Clinical Trial Update: A Safety, Efficacy and Tolerability Study of SEP-225289 [Phase 2]

View source ↗

Summary

This clinical trial update describes the completed Phase 2 study of SEP-225289 in major depressive disorder, assessing safety, efficacy, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SEP-225289

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED